These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 26728266)
1. Molecular targeted therapy for the treatment of gastric cancer. Xu W; Yang Z; Lu N J Exp Clin Cancer Res; 2016 Jan; 35():1. PubMed ID: 26728266 [TBL] [Abstract][Full Text] [Related]
2. Phase I and II clinical trials for gastric cancer. Khushalani NI Surg Oncol Clin N Am; 2012 Jan; 21(1):113-28. PubMed ID: 22098835 [TBL] [Abstract][Full Text] [Related]
7. mTOR as a therapeutic target in patients with gastric cancer. Al-Batran SE; Ducreux M; Ohtsu A Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386 [TBL] [Abstract][Full Text] [Related]
8. Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766 [TBL] [Abstract][Full Text] [Related]
9. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Lee W; Patel JH; Lockhart AC Expert Opin Investig Drugs; 2009 Sep; 18(9):1351-64. PubMed ID: 19642951 [TBL] [Abstract][Full Text] [Related]
10. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575 [TBL] [Abstract][Full Text] [Related]
11. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for gastric adenocarcinoma. Almhanna K Adv Pharmacol; 2012; 65():437-70. PubMed ID: 22959034 [TBL] [Abstract][Full Text] [Related]
13. Targeting HER 2 and angiogenesis in gastric cancer. Jomrich G; Schoppmann SF Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753 [TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies in advanced gastric cancer. Janjigian YY; Shah MA Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in advanced gastric carcinoma: the future is beginning. Schinzari G; Cassano A; Orlandi A; Basso M; Barone C Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282 [TBL] [Abstract][Full Text] [Related]
17. Changing strategies for target therapy in gastric cancer. Lee SY; Oh SC World J Gastroenterol; 2016 Jan; 22(3):1179-89. PubMed ID: 26811656 [TBL] [Abstract][Full Text] [Related]
18. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. Young K; Chau I Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367 [TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Le Tourneau C; Siu LL Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623 [TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer? de Mello RA; de Oliveira J; Antoniou G Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929 [No Abstract] [Full Text] [Related] [Next] [New Search]